Enlighten
Research publications by members of the University of Glasgow
home > services > Enlighten

Blood rheology, cardiovascular risk factors, and cardiovascular disease: The West of Scotland Coronary Prevention Study

Lowe, G., Rumley, A., Norrie, J., Ford, I., Shepherd, J., Cobbe, S., Macfarlane, P., and Packard, C. (2000) Blood rheology, cardiovascular risk factors, and cardiovascular disease: The West of Scotland Coronary Prevention Study. Thrombosis and Haemostasis, 84 (4). pp. 553-558. ISSN 0340-6245

[img]
Preview
Text
Thromb_Haemost84(4)553-558.pdf

233Kb

Publisher's URL: http://www.schattauer.de/z/30_zeitschriften_ihv.asp?load=/zs/thromb/2000/10/ihv.asp

Abstract

The West of Scotland Coronary Prevention Study (WOSCOPS) showed that pravastatin reduced the risk of coronary heart disease (CHD) events in 6,595 middle-aged hypercholesterolaemic men aged 45-64 years without prior myocardial infarction followed for an average of 4.9 years. We hypothesised prospectively (a) that baseline levels of haemorheological variables were related to baseline and incident CHD and to mortality; and (b) that reduction in lipoproteins by pravastatin would lower plasma and blood viscosity, a potential contributory mechanism to CHD events. We therefore studied plasma and blood viscosity, fibrinogen, haematocrit, and blood cell counts at baseline and 1 year. At baseline, plasma and blood viscosity were related to risk factors, CHD measures, and claudication. On univariate analysis, baseline levels of all rheological variables (except platelet count) were related to incident CHD; CHD mortality; and total mortality. On multivariate analysis including baseline CHD and risk factors, plasma and blood viscosity, haematocrit and white cell count each remained significantly associated with incident CHD; while fibrinogen remained an independent predictor of mortality (all p<0.03). After one year, lipoprotein reduction by pravastatin was associated with significant reductions (about one quarter of a standard deviation) in plasma viscosity (mean difference 0.02 mPa.s, p<0.001) and in blood viscosity (mean difference 0.06 mPa.s, p<0.001), but was not associated with significant changes in other rheological variables. We therefore suggest that pravastatin therapy, which reduces elevated lipoproteins in hypercholesterolaemic men, may lower risks of CHD and mortality partly by lowering plasma and blood viscosity. Further studies are required to test this hypothesis.

Item Type:Article
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Macfarlane, Prof Peter and Rumley, Dr Ann and Lowe, Prof Gordon and Norrie, Prof John and Cobbe, Prof Stuart and Packard, Prof Chris and Ford, Prof Ian and Shepherd, Prof James
Authors: Lowe, G., Rumley, A., Norrie, J., Ford, I., Shepherd, J., Cobbe, S., Macfarlane, P., and Packard, C.
Subjects:R Medicine > RC Internal medicine
R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine
R Medicine > RM Therapeutics. Pharmacology
College/School:College of Medical Veterinary and Life Sciences
College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences > Cardiovascular Science
Journal Name:Thrombosis and Haemostasis
Publisher:Schattauer GmbH
ISSN:0340-6245
Copyright Holders:© 2000 Schattauer GmbH
First Published:First published in Thrombosis and Haemostasis 84(4):553-558
Publisher Policy:Reproduced with the permission of the Publisher.

University Staff: Request a correction | Enlighten Editors: Update this record

Downloads per month over past year

View more statistics